Tarsus Pharmaceuticals, Inc. (TARS) has a negative trailing P/E of -45.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 24.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.18%, forward earnings yield 4.14%. PEG 0.54 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -66.9 | 0.00 | -65.13 | 0.00 | - |
| 2019 | -86.0 | 3.81 | -66.86 | 0.00 | - |
| 2020 | -31.3 | -0.07 | 5.06 | 0.00 | - |
| 2021 | -33.4 | 0.68 | 2.77 | 8.11 | - |
| 2022 | -5.8 | -0.02 | 1.87 | 13.98 | - |
| 2023 | -4.4 | -0.05 | 3.02 | 34.10 | - |
| 2024 | -18.0 | 0.54 | 9.27 | 11.38 | - |
| 2025 | -51.5 | 1.07 | 9.96 | 7.58 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.31 | $0.00 | $-1.32M | - |
| 2019 | $-0.24 | $0.00 | $-4.67M | - |
| 2020 | $-1.32 | $0.00 | $-26.81M | - |
| 2021 | $-0.67 | $57.03M | $-13.83M | -24.2% |
| 2022 | $-2.52 | $25.82M | $-62.09M | -240.5% |
| 2023 | $-4.62 | $17.45M | $-135.89M | -778.9% |
| 2024 | $-3.07 | $182.95M | $-115.55M | -63.2% |
| 2025 | $-1.59 | $451.36M | $-66.42M | -14.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.58 | $-0.72 – $-0.47 | $693.87M | $680.26M – $713.33M | 6 |
| 2027 | $3.06 | $2.36 – $4.01 | $901.25M | $900.17M – $902.33M | 4 |
| 2028 | $5.09 | $3.10 – $6.76 | $1.06B | $1.03B – $1.1B | 4 |
| 2029 | $7.00 | $6.77 – $7.35 | $1.2B | $1.17B – $1.25B | 2 |
| 2030 | $9.20 | $8.90 – $9.67 | $1.33B | $1.29B – $1.38B | 2 |
